Johnson & Johnson Reports Positive Long-Term Results for ICOTYDE in Plaque Psoriasis Treatment

Johnson & Johnson reported strong 52-week Phase 3 data for ICOTYDE in plaque psoriasis, achieving high rates of complete skin clearance. Rates increased from 41% to 49% and 33% to 48% between Week 24 and Week 52 in two separate studies. The safety profile remained consistent with earlier data, with no new safety signals identified. In adolescents, ICOTYDE demonstrated sustained efficacy and safety in the ICONIC-LEAD study, with nearly 60% of patients achieving complete skin clearance at Week 52.